lifestyle.trondstidkontroll.com

Author: Arvinas Inc.

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

May 3, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

May 3, 2026
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

March 18, 2026
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

March 11, 2026
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 24, 2026
Arvinas to Participate in Upcoming Investor Conferences

February 23, 2026
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 17, 2026
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

February 12, 2026